125 related articles for article (PubMed ID: 15215131)
1. Purification and characterization of recombinant Staphylococcus haemolyticus DNA gyrase and topoisomerase IV expressed in Escherichia coli.
Bronstein JC; Olson SL; LeVier K; Tomilo M; Weber PC
Antimicrob Agents Chemother; 2004 Jul; 48(7):2708-11. PubMed ID: 15215131
[TBL] [Abstract][Full Text] [Related]
2. Dual inhibition of Staphylococcus aureus DNA gyrase and topoisomerase IV activity by phenylalanine-derived (Z)-5-arylmethylidene rhodanines.
Werner MM; Patel BA; Talele TT; Ashby CR; Li Z; Zauhar RJ
Bioorg Med Chem; 2015 Sep; 23(18):6125-37. PubMed ID: 26320664
[TBL] [Abstract][Full Text] [Related]
3. Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: development of inhibitors with broad spectrum, Gram-negative antibacterial activity.
Trzoss M; Bensen DC; Li X; Chen Z; Lam T; Zhang J; Creighton CJ; Cunningham ML; Kwan B; Stidham M; Nelson K; Brown-Driver V; Castellano A; Shaw KJ; Lightstone FC; Wong SE; Nguyen TB; Finn J; Tari LW
Bioorg Med Chem Lett; 2013 Mar; 23(5):1537-43. PubMed ID: 23294697
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of DNA gyrase and DNA topoisomerase IV of Staphylococcus aureus and Escherichia coli by aminocoumarin antibiotics.
Alt S; Mitchenall LA; Maxwell A; Heide L
J Antimicrob Chemother; 2011 Sep; 66(9):2061-9. PubMed ID: 21693461
[TBL] [Abstract][Full Text] [Related]
5. Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kilodaltons): a single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase.
Bellon S; Parsons JD; Wei Y; Hayakawa K; Swenson LL; Charifson PS; Lippke JA; Aldape R; Gross CH
Antimicrob Agents Chemother; 2004 May; 48(5):1856-64. PubMed ID: 15105144
[TBL] [Abstract][Full Text] [Related]
6. DNA gyrase and DNA topoisomerase of Bacillus subtilis: expression and characterization of recombinant enzymes encoded by the gyrA, gyrB and parC, parE genes.
Barnes MH; LaMarr WA; Foster KA
Protein Expr Purif; 2003 Jun; 29(2):259-64. PubMed ID: 12767818
[TBL] [Abstract][Full Text] [Related]
7. Distribution of gyrase and topoisomerase IV on bacterial nucleoid: implications for nucleoid organization.
Hsu YH; Chung MW; Li TK
Nucleic Acids Res; 2006; 34(10):3128-38. PubMed ID: 16757578
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 4,5,6,7-Tetrahydrobenzo[1,2-d]thiazoles as Novel DNA Gyrase Inhibitors Targeting the ATP-Binding Site.
Tomašič T; Katsamakas S; Hodnik Ž; Ilaš J; Brvar M; Solmajer T; Montalvão S; Tammela P; Banjanac M; Ergović G; Anderluh M; Peterlin Mašič L; Kikelj D
J Med Chem; 2015 Jul; 58(14):5501-21. PubMed ID: 26098163
[TBL] [Abstract][Full Text] [Related]
9. Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.
Mitton-Fry MJ; Brickner SJ; Hamel JC; Brennan L; Casavant JM; Chen M; Chen T; Ding X; Driscoll J; Hardink J; Hoang T; Hua E; Huband MD; Maloney M; Marfat A; McCurdy SP; McLeod D; Plotkin M; Reilly U; Robinson S; Schafer J; Shepard RM; Smith JF; Stone GG; Subramanyam C; Yoon K; Yuan W; Zaniewski RP; Zook C
Bioorg Med Chem Lett; 2013 May; 23(10):2955-61. PubMed ID: 23566517
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, Antimicrobial Activity and Molecular Docking of Novel Thiourea Derivatives Tagged with Thiadiazole, Imidazole and Triazine Moieties as Potential DNA Gyrase and Topoisomerase IV Inhibitors.
Hashem HE; Amr AEE; Nossier ES; Elsayed EA; Azmy EM
Molecules; 2020 Jun; 25(12):. PubMed ID: 32549386
[TBL] [Abstract][Full Text] [Related]
11. Isolation and quantitation of topoisomerase complexes accumulated on Escherichia coli chromosomal DNA.
Aedo S; Tse-Dinh YC
Antimicrob Agents Chemother; 2012 Nov; 56(11):5458-64. PubMed ID: 22869559
[TBL] [Abstract][Full Text] [Related]
12. In Vitro and In Vivo Characterization of the Novel Oxabicyclooctane-Linked Bacterial Topoisomerase Inhibitor AM-8722, a Selective, Potent Inhibitor of Bacterial DNA Gyrase.
Tan CM; Gill CJ; Wu J; Toussaint N; Yin J; Tsuchiya T; Garlisi CG; Kaelin D; Meinke PT; Miesel L; Olsen DB; Lagrutta A; Fukuda H; Kishii R; Takei M; Oohata K; Takeuchi T; Shibue T; Takano H; Nishimura A; Fukuda Y; Singh SB
Antimicrob Agents Chemother; 2016 Aug; 60(8):4830-9. PubMed ID: 27246784
[TBL] [Abstract][Full Text] [Related]
13. Discovery of substituted oxadiazoles as a novel scaffold for DNA gyrase inhibitors.
Jakopin Ž; Ilaš J; Barančoková M; Brvar M; Tammela P; Sollner Dolenc M; Tomašič T; Kikelj D
Eur J Med Chem; 2017 Apr; 130():171-184. PubMed ID: 28246042
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and characterization of novel tetrahydropyran-based bacterial topoisomerase inhibitors with potent anti-gram-positive activity.
Surivet JP; Zumbrunn C; Rueedi G; Hubschwerlen C; Bur D; Bruyère T; Locher H; Ritz D; Keck W; Seiler P; Kohl C; Gauvin JC; Mirre A; Kaegi V; Dos Santos M; Gaertner M; Delers J; Enderlin-Paput M; Boehme M
J Med Chem; 2013 Sep; 56(18):7396-415. PubMed ID: 23968485
[TBL] [Abstract][Full Text] [Related]
15. First functional characterization of a singly expressed bacterial type II topoisomerase: the enzyme from Mycobacterium tuberculosis.
Aubry A; Fisher LM; Jarlier V; Cambau E
Biochem Biophys Res Commun; 2006 Sep; 348(1):158-65. PubMed ID: 16876125
[TBL] [Abstract][Full Text] [Related]
16. DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: synthesis and antibacterial activity.
East SP; White CB; Barker O; Barker S; Bennett J; Brown D; Boyd EA; Brennan C; Chowdhury C; Collins I; Convers-Reignier E; Dymock BW; Fletcher R; Haydon DJ; Gardiner M; Hatcher S; Ingram P; Lancett P; Mortenson P; Papadopoulos K; Smee C; Thomaides-Brears HB; Tye H; Workman J; Czaplewski LG
Bioorg Med Chem Lett; 2009 Feb; 19(3):894-9. PubMed ID: 19095445
[TBL] [Abstract][Full Text] [Related]
17. Bimodal Actions of a Naphthyridone/Aminopiperidine-Based Antibacterial That Targets Gyrase and Topoisomerase IV.
Gibson EG; Oviatt AA; Cacho M; Neuman KC; Chan PF; Osheroff N
Biochemistry; 2019 Nov; 58(44):4447-4455. PubMed ID: 31617352
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Benzothiazole Scaffold-Based DNA Gyrase B Inhibitors.
Gjorgjieva M; Tomašič T; Barančokova M; Katsamakas S; Ilaš J; Tammela P; Peterlin Mašič L; Kikelj D
J Med Chem; 2016 Oct; 59(19):8941-8954. PubMed ID: 27541007
[TBL] [Abstract][Full Text] [Related]
19. Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
Hossion AM; Zamami Y; Kandahary RK; Tsuchiya T; Ogawa W; Iwado A; Sasaki K
J Med Chem; 2011 Jun; 54(11):3686-703. PubMed ID: 21534606
[TBL] [Abstract][Full Text] [Related]
20. Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity.
Tari LW; Trzoss M; Bensen DC; Li X; Chen Z; Lam T; Zhang J; Creighton CJ; Cunningham ML; Kwan B; Stidham M; Shaw KJ; Lightstone FC; Wong SE; Nguyen TB; Nix J; Finn J
Bioorg Med Chem Lett; 2013 Mar; 23(5):1529-36. PubMed ID: 23352267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
